AU Patent

AU2022266680A1 — 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Assigned to Sage Therapeutics LLC · Expires 2023-11-02 · 3y expired

What this patent protects

The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically accep…

USPTO Abstract

The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022266680A1
Jurisdiction
AU
Classification
—
Expires
2023-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.